<DOC>
	<DOC>NCT02116634</DOC>
	<brief_summary>Whether the mesenchymal injection on ALS patients is effective or not?</brief_summary>
	<brief_title>Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>After and before transplantation, all of the patients will visit by experience neurologist and evaluate with EMG (electromyography) and spirometry procedure and clinical progression of disease.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1. sporadic ALS according to escorial criteria 2. onset of disease with spinal cord involvement, Less than 3 years of disease onset with disease progression at 6 past months 3. mild to moderate spinal and bulbar disability,at least having score3 in swallowing, 2 in chewing and waking in ALSFRS and FVC(functional vital capacity) equal or more than 50% of prediction amount 4. normal polysomnography 5. Signed consent form 1. pregnancy or lactation, 2. vascular disease,diabetes, systemic disease as cancer, autoimmune , liver or hematologic disease 3. Hospitalization due to serious illness in the last two months 4. survival time less than two years 5. Hypersensitivity to any component used in the cell culture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>